AI
ByWill Johnson & Johnson’s 2025 Earnings Reinforce Confidence in Its Pharma-Led Growth Engine?
Late January 2026 | Full-Year 2025 Earnings Preview | Diversified Pharma Outlook Johnson & Johnson (J&J) is set…
Can Pfizer’s 2025 Earnings Reignite Confidence in Its Post-COVID Portfolio and Late-Stage Pipeline?
Late January 2026 | Full-Year 2025 Earnings Preview | Big Pharma Strategy Reset Pfizer is set to report…
Will Novartis’ January 2026 Earnings Validate the Strength of Its Focused Portfolio and Late-Stage Pipeline?
January 30, 2026 | Full-Year 2025 Earnings Preview | Innovative Medicines Outlook Novartis is scheduled to report its…
Will Roche’s 2025 Earnings Reset the Narrative for 2026 Growth and Pipeline Confidence?
January 29, 2026 | Full-Year Earnings | Big Pharma Outlook Roche is set to publish its full-year 2025…
GLP-1s: The Thrilling Game-Changer in Obesity—Why Insurers Are Throwing Open the Reimbursement Gates
GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Zepbound) are electrifying the obesity market with unprecedented 15-25% sustained…
Obesity Market Poised for $200B+ US Breakthrough by 2040: A Strategic Gold Rush
The US obesity treatment market, valued at $11-15B in 2024, rockets toward $150-200B by 2040 on 20-25% sustained…
